Drug Classification:

Empagliflozin belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by inhibiting the reabsorption of glucose in the kidneys, thereby promoting the excretion of excess glucose in the urine and lowering blood sugar levels.

Formulations:

• Empagliflozin Tablets:
  • Strength: Available in a formulation containing Empagliflozin 10mg.
  • Product Form: Oral tablets for convenient administration.
  • Packing Specifications: Packaged in blister packs containing 30 tablets each, ensuring easy storage and accessibility.

Indications:

Empagliflozin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Additionally, Empagliflozin has been shown to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with established cardiovascular disease.

Usage:

• Empagliflozin Tablets should be taken orally once daily, with or without food.
• It is important to follow the prescribed dosage and regimen recommended by your healthcare provider.
• Regular monitoring of blood glucose levels and kidney function is essential during treatment with Empagliflozin.

Dosage:

• The recommended dosage of Empagliflozin Tablets is 10 mg once daily.
• Dose adjustment may be necessary based on individual patient factors such as renal function and tolerability.
• Empagliflozin can be used as monotherapy or in combination with other antidiabetic medications.

Pharmacokinetics:

• Empagliflozin is rapidly absorbed after oral administration, with peak plasma concentrations achieved within 1.5 hours.
• It is primarily metabolized in the liver via glucuronidation and hydroxylation pathways, with renal excretion of metabolites.
• The elimination half-life of Empagliflozin is approximately 12.4 hours.

Pharmacodynamics:

• Empagliflozin inhibits the SGLT2 transporter in the proximal renal tubules, leading to increased urinary glucose excretion and reduced reabsorption of glucose from the urine.
• This mechanism of action helps to lower blood glucose levels independently of insulin secretion or action.

Side Effects:

• Common side effects of Empagliflozin Tablets may include urinary tract infections, genital yeast infections, and increased urination.
• Other potential side effects may include hypoglycemia (especially when used in combination with insulin or insulin secretagogues), dehydration, and hypotension.
• Contact your healthcare provider if you experience any persistent or severe side effects while taking Empagliflozin Tablets.

Experience the benefits of Empagliflozin Tablets from AIT Pharmaceuticals Division. Trust in our commitment to providing high-quality medications to support the management of type 2 diabetes mellitus and improve cardiovascular outcomes. For more information, please visit our website or consult your healthcare provider.